Literature DB >> 16597462

Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu.

Matthew A Joseph1, Megan L Mitchell, Jeffrey D Evanseck, Jeffrey R Kovacs, Liang Jia, Hongmei Shen, Wilson S Meng.   

Abstract

We investigated analogues of GP2 (IISAVVGIL), an HLA-A*0201-restricted T-cell epitope derived from residues 654-662 in the tumor-associated antigen (TAA) Her-2/neu. One limiting factor of GP2 is its poor affinity for HLA-A*0201. Conformational analysis revealed the P5-P7 region in GP2 appears to be linked to the stability of P9 side chain interaction with the MHC molecule. To identify variants of GP2 with enhanced presentation to HLA-A*0201, we tested V6S, V6T, V6Q, G7P, G7F, T6F7, and Q6F7 for their capacity to stabilize cell surface HLA-A*0201 molecules. Of the mono-substituted variants, V6Q and G7F exhibited superior stabilization as compared to GP2. Molecular dynamics simulations suggest the improved binding can be attributed to concerted motions in the central and C-terminal regions of the peptide. These data support the notion that amino acids in HLA-A*0201 epitopes may be inter-dependent. Priming HLA-A*0201 transgenic mice with G7F-loaded syngeneic dendritic cells stimulated mouse T cells to produce a higher level of INFgamma than mice immunized with GP2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597462      PMCID: PMC2430429          DOI: 10.1016/j.molimm.2006.02.027

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  42 in total

1.  Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells.

Authors:  H J Zweerink; M C Gammon; U Utz; S Y Sauma; T Harrer; J C Hawkins; R P Johnson; A Sirotina; J D Hermes; B D Walker
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

2.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

3.  A model of water structure inside the HLA-A2 peptide binding groove.

Authors:  W S Meng; H von Grafenstein; I S Haworth
Journal:  Int Immunol       Date:  1997-09       Impact factor: 4.823

4.  The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.

Authors:  M Peiper; P S Goedegebuure; D C Linehan; E Ganguly; C C Douville; T J Eberlein
Journal:  Eur J Immunol       Date:  1997-05       Impact factor: 5.532

5.  Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53.

Authors:  K J Smith; S W Reid; K Harlos; A J McMichael; D I Stuart; J I Bell; E Y Jones
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

6.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.

Authors:  S H van der Burg; M J Visseren; R M Brandt; W M Kast; C J Melief
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

7.  Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove.

Authors:  D H Fremont; E A Stura; M Matsumura; P A Peterson; I A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.

Authors:  A Ribas; L H Butterfield; W H McBride; S M Jilani; L A Bui; C M Vollmer; R Lau; V B Dissette; B Hu; A Y Chen; J A Glaspy; J S Economou
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

9.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Authors:  M R Parkhurst; M L Salgaller; S Southwood; P F Robbins; A Sette; S A Rosenberg; Y Kawakami
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

10.  Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice.

Authors:  P A Wentworth; A Vitiello; J Sidney; E Keogh; R W Chesnut; H Grey; A Sette
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

View more
  4 in total

1.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay.

Authors:  Mikkel Harndahl; Michael Rasmussen; Gustav Roder; Søren Buus
Journal:  J Immunol Methods       Date:  2010-10-31       Impact factor: 2.303

Review 2.  Peptide mimotopes alter T cell function in cancer and autoimmunity.

Authors:  Jill E Slansky; Maki Nakayama
Journal:  Semin Immunol       Date:  2020-03-20       Impact factor: 11.130

3.  Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules.

Authors:  Kyle R Jackson; Dinler A Antunes; Amjad H Talukder; Ariana R Maleki; Kano Amagai; Avery Salmon; Arjun S Katailiha; Yulun Chiu; Romanos Fasoulis; Maurício Menegatti Rigo; Jayvee R Abella; Brenda D Melendez; Fenge Li; Yimo Sun; Heather M Sonnemann; Vladislav Belousov; Felix Frenkel; Sune Justesen; Aman Makaju; Yang Liu; David Horn; Daniel Lopez-Ferrer; Andreas F Huhmer; Patrick Hwu; Jason Roszik; David Hawke; Lydia E Kavraki; Gregory Lizée
Journal:  PNAS Nexus       Date:  2022-07-27

4.  Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance.

Authors:  Sietske K Rosendahl Huber; Jolien J Luimstra; Josine van Beek; Rieuwert Hoppes; Ronald H J Jacobi; Marion Hendriks; Kim Kapteijn; Casper Ouwerkerk; Boris Rodenko; Huib Ovaa; Jørgen de Jonge
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.